ESMO 2012: Roche underscores leadership in oncology with new data in HER2 positive breast cancer and skin cancer Montag, 24. September 2012 - 07:08

ESMO 2012: Roche underscores leadership in oncology with new data in HER2 positive breast cancer and skin cancer

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that data on thirteen of its investigational and approved products will be presented at the European Society for Medical Oncology (ESMO) Congress taking place in Vienna, Austria on 28 September - 2 October 2012. 

During the past 50 years Roche has developed and secured approval for ten cancer medicines. The data presented at ESMO 2012 reflect not only the continuing role being played by Roche’s early discoveries, but also the potential of the company’s newer treatments. Highlights will include data on personalised medicines from the company’s HER2 and skin cancer franchises.

"Our mission is to develop therapies that transform medicine," said Hal Barron M.D., Chief Medical Officer and Head, Global Product Development. "The improvement in survival with trastuzumab emtansine (T-DM1) and other data presented at ESMO reflect our commitment to make a real difference for people living with cancer."

more

With best regards, Roche Group Media Relations

Roche Group Communications Grenzacherstrasse 124 4070 Basel, Switzerland

Phone: +41 61 688 88 88 Fax: +41 61 688 27 75 mailto:roche.mediarelations@roche.com www.roche.com